# Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

> **NCT01579474** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 131 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** BI 201335 high dose
- **DRUG:** BI 201335 low dose
- **DRUG:** BI 201335 high dose
- **DRUG:** BI 201335 high dose

## Key facts

- **NCT ID:** NCT01579474
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2015-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579474, "Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01579474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*